Accuray Incorporated
As of Oct 22, 2026, Accuray is in Stage 4, the downtrend phase, now in week 48 (since Nov 12, 2025). It closed at $0.13, 91.9% below its 52-week high and below its 200-day average, which is falling.
Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin Amer… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ARAY early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ARAY among Medical Devices120th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …120 | ARAY | Stage 4 · wk 48 | 6 | −43.5% |
Accuray: quick answers
What stage is Accuray in?
As of Oct 22, 2026, Accuray (ARAY) is in Stage 4, the downtrend phase. It entered Stage 4 on Nov 12, 2025 and is in week 48. What the four stages mean
Is Accuray in an uptrend?
No. Accuray is in a Stage 4 downtrend. It trades 66.7% below its 200-day average, which is falling.
How far is Accuray from its 52-week high?
Accuray closed at $0.13 on Oct 22, 2026, 91.9% below its 52-week high of $1.61. Its 52-week low is $0.13.
How has Accuray performed over the past year?
As of Oct 22, 2026, Accuray is down 91.9% over the past year and down 84.7% so far in 2026.
Which sector and industry is Accuray in?
Accuray is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.